Positive CHMP opinion for Epidyolex® in TSC-associated epilepsy
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for Epidyolex® (cannabidiol) as a treatment option for TSC-associated epilepsy in people aged two years and older. The update is a major hurdle crossed in the journey

